Evidence map›Paper›PMID 34887575›Full record

ArticleNature medicine2021

A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.

Peng Zhang, Elisabeth Narayanan, Qingbo Liu, Yaroslav Tsybovsky, Kristin Boswell, Shilei Ding, Zonghui Hu, Dean Follmann, Yin Lin, Huiyi Miao and 26 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed
16.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 161 citations in OpenAlex.

  1. Article
  2. Article
  3. Acta pharmaceutica Sinica. B · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Rational design of lipid nanoparticles for enabling gene therapies.Molecular therapy. Methods & clinical development · 2025
    Review
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors at 6 institutions in 2 countries.

Peng ZhangLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA.
Elisabeth NarayananModerna Inc., Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8836-181X
Qingbo LiuLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1347-6636
Yaroslav TsybovskyCancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Kristin BoswellVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Shilei DingUniversité de Montreal, Montreal, Quebec, Canada.
Zonghui HuBiostatistics Research Branch, NIAID, NIH, Bethesda, MD, USA.
Dean FollmannBiostatistics Research Branch, NIAID, NIH, Bethesda, MD, USA.
Yin LinLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA.
Huiyi MiaoLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA.
Hana SchmeisserLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA.
Denise RogersLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA.
Samantha FalconeModerna Inc., Cambridge, MA, USA.
Sayda M ElbashirModerna Inc., Cambridge, MA, USA.
Vladimir PresnyakModerna Inc., Cambridge, MA, USA.
Kapil BahlModerna Inc., Cambridge, MA, USA.
Madhu PrabhakaranVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Xuejun ChenVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-9192-0440
Edward K SarfoVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-9015-3446
David R AmbrozakVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Rajeev GautamLaboratory of Molecular Microbiology, NIAID, NIH, Bethesda, MD, USA.
Malcom A MartinLaboratory of Molecular Microbiology, NIAID, NIH, Bethesda, MD, USA.
Joanna SwerczekExperimental Primate Virology Section, NIAID, Poolesville, MD, USA.
Richard HerbertExperimental Primate Virology Section, NIAID, Poolesville, MD, USA.
Deborah WeissBioqual Inc., Rockville, MD, USA.
Johnathan MisamoreBioqual Inc., Rockville, MD, USA.
Giuseppe CiaramellaModerna Inc., Cambridge, MA, USA.
Sunny HimansuModerna Inc., Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7954-9674
Guillaume Stewart-JonesModerna Inc., Cambridge, MA, USA.
Adrian McDermottVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-0616-9117
Richard A KoupVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
John R MascolaVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Andrés FinziUniversité de Montreal, Montreal, Quebec, Canada.
Andrea CarfiModerna Inc., Cambridge, MA, USA.
Anthony S FauciLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA.
Paolo LussoLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA. plusso@niaid.nih.gov.ORCID http://orcid.org/0000-0002-2813-4081
Moderna Therapeutics (United States) · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USBioqual · USUniversité de Montréal · CALeidos (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of a protective vaccine remains a top priority for the control of the HIV/AIDS pandemic. Here, we show that a messenger RNA (mRNA) vaccine co-expressing membrane-anchored HIV-1 envelope (Env) and simian immunodeficiency virus (SIV) Gag proteins to generate virus-like particles (VLPs) induces antibodies capable of broad neutralization and reduces the risk of infection in rhesus macaques. In mice, immunization with co-formulated env and gag mRNAs was superior to env mRNA alone in inducing neutralizing antibodies. Macaques were primed with a transmitted-founder clade-B env mRNA lacking the N276 glycan, followed by multiple booster immunizations with glycan-repaired autologous and subsequently bivalent heterologous envs (clades A and C). This regimen was highly immunogenic and elicited neutralizing antibodies against the most prevalent (tier-2) HIV-1 strains accompanied by robust anti-Env CD4

Indexed as

Genes, envGenes, gagAnimalsAntibodies, NeutralizingHIV-1HIV AntibodiesImmunization, SecondaryMacaca mulattamRNA VaccinesRisk FactorsSimian Acquired Immunodeficiency SyndromeVaccines, SyntheticAntibodies, NeutralizingHIV AntibodiesmRNA VaccinesVaccines, Synthetic

Identifiers

PMID34887575
OpenAlexW4200069835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.